The bioengineered products used for non-healing wounds of lower extremity are Wound care biologics. Usage involves of active biological agents such as plant and animal-derived biomolecules which exhibits antioxidant and antimicrobial properties. They used in the post surgeries and trauma cases as they provide moist healing environment aiding heat loss, protein, and prevent bacterial contamination.
Demand for various products are also been manufactured to replace or augment various substrates in the wound healing cascade. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination.
Key Growth Drivers and Opportunities
Increasing incidence of traumatic: Growing incidences of traumatic, surgical, ulcers and burn wounds are the major driver factor of wound care biologics. In 2017, according to global diabetes community it was estimated that 422 million adults are living with diabetes globally, and this is expected to increase to 642 million by 2040.
Challenges
The higher cost tag associated with biologics and the tough regulatory hurdles for bringing new tissue-engineered products to market are holding back the growth of the wound care biologics sector. Smaller healthcare centers frequently find it tough to pay for or keep these cutting-edge treatments on hand, which limits patients’ ability to get them.
Innovation and Expansion
Convatec Enters Biologics Market with Triad Life Sciences Acquisition
In March 2022, Convatec Group Plc made a move by acquiring Triad Life Sciences Inc., a medical device company from the United States. Triad focused on creating products from biological sources to help heal surgical wounds, chronic wounds, and burns.
For Convatec, purchasing Triad was a truly significant step. It allowed them to enter the market for biological wound care solutions, providing them with more tools to address medical needs that had previously gone unmet.
MIMEDX Gains Japan Approval, Expands Global Footprint with Epifix
In June 2021, MIMEDX (US) received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan.
MIMEDX, a US-based company, has received the green light from Japan’s Ministry of Health, Labour and Welfare to bring Epifix to market in Japan. This news is a big deal and marks a major step forward for the company’s plans to expand its reach around the world.
Inventive Sparks, Expanding Markets
Key players operating in the wound care biologics market includes Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, among others. Companies in the wound care biologics sector are focused on providing cutting-edge healing options that speed up recovery and enhance the quality of life for patients.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
